Gilead’s Four Drug Launches Could Rewrite the HIV Has-Been Narrative

What happened

Gilead Sciences, long pigeonholed as a mature HIV franchise, is positioning for a growth inflection with four key drug launches in 2026. The company’s Q1’26 results show core HIV sales up 9.6% to $5.03B, while PrEP drug Yeztugo generated $166M in its first full quarter and is on track to hit ~$1B for the year. Meanwhile, the FDA will decide on bictegravir/lenacapavir (BIC/LEN) by August 27, 2026, and on anito-cel by December 23, 2026, with an oral once-weekly Yeztugo decision due in early 2027. Despite a guided full-year GAAP net loss from ~$11.5B in acquisition-related IPR&D charges, operating cash flow remains robust at $2.5B in Q1, and the Biktarvy patent settlement pushes generic entry to 2036. The market continues to discount the stock at 16.8x trailing earnings, but the upcoming catalyst cadence—if executed—could force a re-rating as the “has-been” label fades.

Implication

For investors, the next 6–12 months hinge on three binary events: BIC/LEN approval (Aug), Yeztugo scaling past $250M/quarter, and anito-cel’s PDUFA (Dec). If all three hit, the earnings normalization post-2026 could support a $135–155 stock (base–bull case). However, if Yeztugo stalls at coverage without utilization or if anito-cel gets a CRL, the stock could test $95. The thesis is that 2026’s accounting loss obscures durable HIV cash flows, and the four launches provide optionality beyond HIV. Patience is required, but the risk/reward is favorable at $124 with a safety net from Biktarvy’s exclusivity and $7.6B cash.

Thesis delta

Increased conviction that the 2026 GAAP loss is transitory and that four upcoming launches—BIC/LEN, anito-cel, oral Yeztugo, and existing Yeztugo scale—can shift Gilead from a single-franchise HIV story to a multi-pipeline growth company, warranting a higher multiple once earnings visibility improves.